Sanofi-Synthelabo May Enter India Via Aventis

Mumbai, April 26 | Updated: Apr 27 2004, 05:30am hrs
Global healthcare major Sanofi-Synthelabo will now have a presence in India through a wholly-owned subsidiary Sanofi-Synthelabo (India) and Aventis Pharma Ltd, which is a 50.1 per cent subsidiary.

Top officials at Sanofi-Synthelabo (India) refrained from making a comment on the Indian impact of the merger, due to lack of clarity. Analyst tracking the sector said that it would take another year before a decision on the Indian subsidiaries is taken.

Sanofi-Synthelabo started its operations in India in 1997 as a joint-venture company. In 2002, it became a 100 per cent subsidiary of Sanofi-Synthelabo, France. The Indian wholly owned subsidiary, as per the IMS data (MAT Feb 04) has a sales turnover of over Rs 60 crore, according to company officials.

The company is present in cardiology, thrombosis & neuropsychiatry with a sales force numbering around 180.

Aventis Pharma in India has a turnover of Rs 651.6 crore with leading brands including Allegra, Cardace and Amaryl. It has two manufacturing facilities located at Ankleshwar and Goa.